TBK1 and hepatocellular carcinoma: Tiliroside, a robust tank-binding kinase-1 (TBK1) inhibitor, has emerged as a promising natural compound capable of augmenting the effectiveness of sorafenib in HCC therapy by targeting TBK1 and inducing ferroptosis [76].